Literature DB >> 16790275

Identification of a constitutively active mutant of JAK3 by retroviral expression screening.

Young Lim Choi1, Ruri Kaneda, Tomoaki Wada, Shin-Ichiro Fujiwara, Manabu Soda, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Hiroyuki Mano.   

Abstract

To identify transforming genes in acute myeloid leukemia (AML) we here constructed a retroviral cDNA expression library from an AML patient, and then used this library to infect a mouse cell line 32Dcl3-mCAT. cDNA inserts of the cell clones which proliferated in the presence of granulocyte colony-stimulating factor were derived from JAK3 encoding a JAK3 mutant with a valine-to-alanine substitution at codon 674 and two additional amino acid substitutions. The transforming activity of JAK3(V674A) was confirmed by its introduction into 32Dcl3-mCAT. Sequencing of the original JAK3 cDNA derived from the patient, however, failed to detect the V674A mutation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790275     DOI: 10.1016/j.leukres.2006.05.006

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient.

Authors:  Sachiko Kawashima-Goto; Toshihiko Imamura; Masafumi Seki; Motohiro Kato; Kenichi Yoshida; Atsuya Sugimoto; Daisuke Kaneda; Atsushi Fujiki; Mitsuru Miyachi; Takuya Nakatani; Shinya Osone; Hiroyuki Ishida; Tomohiko Taki; Junko Takita; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Seishi Ogawa; Hajime Hosoi
Journal:  Int J Hematol       Date:  2014-11-28       Impact factor: 2.490

2.  Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats.

Authors:  Byung-Hak Kim; Myunghwan Kim; Chang-Hong Yin; Jun-Goo Jee; Claudio Sandoval; Hyejung Lee; Erika A Bach; Dae-Hyun Hahm; Gyeong-Hun Baeg
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.

Authors:  Byung-Hak Kim; Jun-Goo Jee; Chang-Hong Yin; Claudio Sandoval; Somasundaram Jayabose; Daisuke Kitamura; Erika A Bach; Gyeong-Hun Baeg
Journal:  Mol Cancer       Date:  2010-02-11       Impact factor: 27.401

4.  A mouse model for EML4-ALK-positive lung cancer.

Authors:  Manabu Soda; Shuji Takada; Kengo Takeuchi; Young Lim Choi; Munehiro Enomoto; Toshihide Ueno; Hidenori Haruta; Toru Hamada; Yoshihiro Yamashita; Yuichi Ishikawa; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

Review 5.  The EML4-ALK oncogene: targeting an essential growth driver in human cancer.

Authors:  Hiroyuki Mano
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2015       Impact factor: 3.493

6.  Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.

Authors:  Byung-Hak Kim; Eun Hee Yi; Jun-Goo Jee; Ae Jin Jeong; Claudio Sandoval; In-Chul Park; Gyeong Hun Baeg; Sang-Kyu Ye
Journal:  J Cell Mol Med       Date:  2020-06-17       Impact factor: 5.310

7.  Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.

Authors:  Louise van der Weyden; George Giotopoulos; Kim Wong; Alistair G Rust; Carla Daniela Robles-Espinoza; Hikari Osaki; Brian J Huntly; David J Adams
Journal:  BMC Cancer       Date:  2015-08-13       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.